XAIR

Beyond Air Inc

Add to Watchlist

Advanced Chart

3.010

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.010

Open

3.010

VWAP

3.01

Vol

3.81K

Mkt Cap

13.97M

Low

3.010

Amount

11.47K

EV/EBITDA(TTM)

Total Shares

45.90M

17.61M

EV/OCF(TTM)

P/S(TTM)

54.97

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

3.79M

+253.31%

2.55M

+219.71%

1.75M

+155.97%

Estimates Revision

The market is revising Upward the revenue expectations for Beyond Air, Inc. (XAIR) for FY2026, with the revenue forecasts being adjusted by 13.68% over the past three months. During the same period, the stock price has changed by -29.51%.

Revenue Estimates for FY2026

Revise Upward

+13.68%

In Past 3 Month

Stock Price

Go Down

-29.51%

In Past 3 Month

4 Analyst Rating

24.58% Upside

Wall Street analysts forecast XAIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XAIR is 3.75 USD with a low forecast of 1.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

24.58% Upside

Current: 3.010

Low

1.00

Averages

3.75

High

11.00

24.58% Upside

Current: 3.010

Low

1.00

Averages

3.75

High

11.00

D. Boral Capital

Jason Kolbert

initiated

$11

2025-07-17

Reason

D. Boral Capital

Jason Kolbert

Price Target

$11

2025-07-17

initiated

Reason

D. Boral Capital analyst Jason Kolbert initiated coverage of Beyond Air with a Buy rating and $11 price target. The firm says the company's LungFit platform represents a "disruptive leap" in nitric oxide delivery. It enables on-demand generation from ambient air without the need for high-pressure gas cylinders or chemical cassettes, the analyst tells investors in a research note. Boral believes new indications represent out-year revenue drivers for Beyond Air.

Roth MKM

Jason White

Strong Buy

Initiates

2024-08-16

Reason

Roth MKM

Jason White

Price Target

2024-08-16

Initiates

Strong Buy

Reason

Piper Sandler

Jason Bednar

Buy

Maintains

$3.5 → $1

2024-08-07

Reason

Piper Sandler

Jason Bednar

Price Target

$3.5 → $1

2024-08-07

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Beyond Air Inc (XAIR.O) is -0.73, compared to its 5-year average forward P/E of -2.50. For a more detailed relative valuation and DCF analysis to assess Beyond Air Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.50

Current PE

-0.73

Overvalued PE

1.40

Undervalued PE

-6.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.45

Current EV/EBITDA

-29.11

Overvalued EV/EBITDA

2.95

Undervalued EV/EBITDA

-7.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

42.02

Current PS

0.93

Overvalued PS

119.83

Undervalued PS

-35.79